How many clinical trials are studying Cabozantinib S-malate?

4 recruiting trials in our tracked data involve Cabozantinib S-malate.

What conditions is Cabozantinib S-malate being studied for?

In our tracked recruiting trials, Cabozantinib S-malate is being studied in trials for Prostate cancer, Stage IV Renal Cell Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8.

Cabozantinib S-malate: clinical trials recruiting now

Q: Is Cabozantinib S-malate FDA-approved?

Yes. According to the FDA drug label available through openFDA, Cabozantinib S-malate is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Cabozantinib S-malate appears in the FDA drug-label database. Marketed as COMETRIQ.

FDA-approved use

COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). ( 1 )

FDA label via openFDA

Phase breakdown

Phase 1 1 Phase 2 3

Conditions being studied

Condition	Trials
Prostate cancer	2
Stage IV Renal Cell Cancer AJCC v8	2
Stage IVB Prostate Cancer AJCC v8	2
Advanced Breast Carcinoma	1
Advanced Endometrial Carcinoma	1
Advanced Fallopian Tube Carcinoma	1
Advanced Hepatocellular Carcinoma	1
Advanced Malignant Abdominal Neoplasm	1
Advanced Malignant Female Reproductive System Neoplasm	1
Advanced Malignant Thoracic Neoplasm	1
Advanced Ovarian Carcinoma	1
Advanced Primary Peritoneal Carcinoma	1
Advanced Renal Cell Carcinoma	1
Anatomic Stage III Breast Cancer AJCC v8	1
Anatomic Stage IIIA Breast Cancer AJCC v8	1

Recruiting trials involving Cabozantinib S-malate

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 229 locations
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT05168618 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT05092373 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 581 locations

Common questions

Is Cabozantinib S-malate FDA-approved?

Yes, marketed as COMETRIQ.

How many recruiting trials involve Cabozantinib S-malate?

4 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.